Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Long-term commercial use outcomes with hydrogel near vision inlay in the correction of presbyopia

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Refractive Corneal Inlays

Session Date/Time: Monday 12/09/2016 | 15:00-16:30

Paper Time: 15:40

Venue: Poster Village: Pod 2

First Author: : C.Verdoorn THE NETHERLANDS

Co Author(s): :                  

Abstract Details

Purpose:

To report my long term commercial outcomes in patients implanted unilaterally with the Raindrop® Near Vision Inlay (ReVision Optics, Inc., Lake Forest, CA, USA) for the treatment of presbyopia

Setting:

Lasikcentrum Oogkliniek , Boxtel, The Netherlands

Methods:

Twenty-one (n=21) patients were implanted with the Raindrop Inlay in the non-dominant eye after creating a femtosecond LASIK flap at 150 microns depth and 8 mm diameter. Concurrent laser ablation was performed on 13 of the 21 patients with a targeted refraction of +0.75 D in the inlay eye. Postoperative measurements included: visual acuities, manifest refraction, topography, and slit lamp images

Results:

Patients (mean age: 54 years old, range 47-61) had an average postop period of 21 months. All patients achieved binocular uncorrected distance VA of 1.0 or better. 70% of the patients achieved binocular uncorrected near VA of 1.0. Two inlays were explanted: one due to recurrent haze and one for binocular imbalance (after 1.5 and 2 years respectively). Normal topograghical changes with Raindrop and complication management will be shared at the meeting

Conclusions:

Raindrop Inlay is an effective tool for correcting presbyopia in my practice. My long term data show consistent improvements at near and intermediate vision. To ensure continued success and minimal complications, patients should be followed up every 6-12 months

Financial Disclosure:

One or more of the authors receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to previous